Showing 6661-6670 of 8823 results for "".
- Scaravoid May Offer A New Approach to Wound Healinghttps://practicaldermatology.com/news/scaravoid-may-offer-a-new-approach-to-wound-healing/2460126/A new foam that is placed in skin wounds to support and optimize the natural healing process may help prevent scarring. With the "Scaravoid" project, Markus Rottmar, PhD and his team at Empa's Biointerfaces lab
- MoleSafe USA Launches Interactive Challenge for Skin Cancer Awareness Monthhttps://practicaldermatology.com/news/molesafe-usa-launches-interactive-challenge-for-skin-cancer-awareness-month/2460019/MoleSafe USA, LLC is launching an interactive, online
- InMode Launches AccuTite, the Smallest RFAL Treatment for Face and Bodyhttps://practicaldermatology.com/news/inmode-launches-accutite-the-smallest-rfal-treatment-for-face-and-body/2460000/InMode Ltd
- La Roche-Posay to Sponsor a Patient to Visit Thermal Dermatology Center: Accepting Nominationshttps://practicaldermatology.com/news/la-roche-posay-to-sponsor-a-patient-to-visit-thermal-dermatology-center-accepting-nominations/2459995/La Roche-Posay brand is sponsoring a patient to travel to the Thermal Dermatology center in the town of La Roche-Posay, France this fall. With 8,000 visitors per year, a third of whom are children, the La Roche-Posay thermal center is Europe’s leading thermal dermatology center for sensitiv
- Immunotherapy Appears Better Than Chemotherapy for Aggressive Merkle Cell Carcinomahttps://practicaldermatology.com/news/immunotherapy-appears-better-than-chemotherapy-for-aggressive-merkle-cell-carcinoma/2459909/First-line therapy with Pembrolizumab may produce better responses and result in longer survival in Merkel cell carcinoma than conventional chemotherapy. The study, co-led by Suzanne Topa
- Encore Dermatology Announces Phase 2 Safety Data for Impoyzhttps://practicaldermatology.com/news/encore-dermatology-announces-phase-2-safety-data-for-impoyz/2457496/A Phase 2, open-label study published in SKIN The Journal of Cutaneous Medicine, found that subjects treated with Impoyz (clobetasol propionate) Cream, 0.025% showed significantly lower mean post-treatment clobetasol propionate plasma concentrations versus the subjects treated with Temov
- Alastin Skincare's Latest Product May Become Body Contouring Procedures' New BFFhttps://practicaldermatology.com/news/alastin-skincares-latest-product-may-be-body-contouring-procedures-new-bff/2457573/
- Veloce BioPharma Announces Positive Phase 2b Study Results for VBP-926 for Chemotherapy-Associated Paronychiahttps://practicaldermatology.com/news/veloce-biopharma-announces-positive-phase-2b-study-results-for-vbp-926-for-chemotherapy-associated-paronychia/2457580/Veloce BioPharma, LLC, a clinical-stage biopharmaceutical company dedicated to developing topical therapeutics for unmet needs in dermatologic and ophthalmic diseases, shared positive results of its Phase 2b study of dilute povidone-iodine in a novel DMSO solvent system for the topical treatment
- Mayo Clinic Doctors Receive Stand Up to Cancer Catalyst Award for Melanoma Researchhttps://practicaldermatology.com/news/mayo-clinic-doctors-receive-stand-up-to-cancer-catalyst-award-for-melanoma-research/2457617/Mayo Clinic immunologist and medical oncologist Matthew Block, M.D., Ph.D. and surgeon Tina Hieken, M.D., received a
- Report: Psoriasis in America in 2018https://practicaldermatology.com/news/report-psoriasis-in-america-in-2018/2457640/Recently released psoriasis survey results reveal that only 10 percent of patients feel their condition is under control with their current treatment plans; meanwhile, their symptoms—and the mental emotional effects of those symptoms—are overwhelming. The survey, "